MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7651-7662

  Codo, Paula ^a   Weller, Michael ^a   Meister, Gunter ^b   Szabo, Emese ^a   Steinle, Alexander ^c   Wolter, Marietta ^d   Reifenberger, Guido ^d   Roth, Patrick ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Glioma; Immune escape; miRNA; NKG2D

Indexed keywords

BINDING PROTEIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MHC CLASS I CHAIN RELATED MOLECULE A; MHC CLASS I CHAIN RELATED MOLECULE B; MICRORNA; MICRORNA 106B; MICRORNA 20A; MICRORNA 302; MICRORNA 372; MICRORNA 373; MICRORNA 93; NATURAL KILLER CELL RECEPTOR NKG2D; NKG2D LIGAND; UL16 BINDING PROTEIN 2; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; SIGNAL PEPTIDE;

ARTICLE; CELL HYPOXIA; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION; TUMOR ESCAPE; UPREGULATION; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CANCER STEM CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOMA; IMMUNOLOGY; METABOLISM; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GPI-LINKED PROTEINS; HETEROGRAFTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR ESCAPE;

EID: 84907546541     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2287     Document Type: Article

References (36)

1. Weller M and Wick W. Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma. Nat Rev Neurol. 2014; 10(2):68-70.
2. Ullrich E, Koch J, Cerwenka A and Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013; 2(10):e26097.
3. Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D and Smyth MJ. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol. 2002; 169(10):5377-5381.
4. Raulet DH, Gasser S, Gowen BG, Deng W and Jung H. Regulation of ligands for the NKG2D activating receptor. Annual review of immunology. 2013; 31:413-441.
5. Fernandez-Messina L, Reyburn HT and Vales-Gomez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Frontiers in immunology. 2012; 3:299.
6. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Buhring HJ, Dichgans J, Rammensee HG, Steinle A and Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003; 63(24):8996-9006.
7. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A and Weller M. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004; 64(20):7596-7603.
8. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M and Friese MA. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006; 129(Pt 9):2416-2425.
9. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL and Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 2010; 12(1):7-13.
10. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M and Mandelboim O. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nature immunology. 2008; 9(9):1065-1073.
11. Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, Lankry D and Mandelboim O. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res. 2012; 72(21):5463-5472.
12. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D and Paschen A. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012; 72(2):460-471.
13. Godlewski J, Newton HB, Chiocca EA and Lawler SE. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ. 2010; 17(2):221-228.
14. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20.
15. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W and Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011; 6(1):e16195.
16. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708.
17. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-722.
18. Roth P, Eisele G and Weller M. Immunology of brain tumors. Handb Clin Neurol. 2012; 104:45-51.
19. Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012; 18(12):1827-1834.
20. Cantini G, Pisati F, Pessina S, Finocchiaro G and Pellegatta S. Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology. 2012; 1(6):884-893.
21. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M and Weller M. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res. 2007; 67(8):3540-3544.
22. Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M and Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010; 16(15):3851-3859.
23. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 2009; 182(6):3530-3539.
24. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC and Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res. 2010; 16(13):3399-3408.
25. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM and Mari B. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell death & disease. 2013; 4:e544.
26. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR and Graham CH. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011; 71(24):7433-7441.
27. Yamada N, Yamanegi K, Ohyama H, Hata M, Nakasho K, Futani H, Okamura H and Terada N. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1alpha-dependent manner. Int J Oncol. 2012; 41(6):2005-2012.
28. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S and Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327(5962):198-201.
29. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014; 111(1):409-414.
30. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M and Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008; 27(20):2897-2909.
31. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G and Hanash SM. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol. 2003; 163(3):1033-1043.
32. Carraro G, Albertin G, Forneris M and Nussdorfer GG. Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol Cell Probes. 2005; 19(3):181-186.
33. Nytko KJ, Maeda N, Schlafli P, Spielmann P, Wenger RH and Stiehl DP. Vitamin C is dispensable for oxygen sensing in vivo. Blood. 2011; 117(20):5485-5493.
34. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M and Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3):449-457.
35. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG and Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003; 102(4):1389-1396.
36. Beitzinger M, Peters L, Zhu JY, Kremmer E and Meister G. Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol. 2007; 4(2):76-84.